subgroup of MN, the homogeneous type with EM findings of synchronous electron-dense deposits, but Background. A considerable diversity in prognosis is seen with membranous nephropathy (MN ). A recent does not alter the long-term outcome of human MN. report showed beneficial effects of immune globulin
ment with intravenous immune globulin, steroid alone or treated with intravenous immune globulin therapy and together with immunosuppressants, or no treatment, were 56 historical controls. We also divided membranous judged in the same way. Clinical status was defined as nephropathy into two subtypes based on electron follows: the nephrotic state, the presence of heavy proteinuria microscopic findings; i.e. homogeneous type with syn-(greater than 3.5 g/day or 3+ (300 mg/dl ) to 4+ (1000 chronous electron-dense deposits and heterogeneous mg/dl ) by Multistics) and hypoalbuminaemia ( levels less type with various stages of dense deposits.
than 30 g/l ); incomplete remission type II, i.e. normal serum albumin levels (more than 30 g/litre) with a mean daily proteinuria of 1.0-3.5 g for 7 consecutive days or 2+
Subjects and methods
(100 mg/dl ) to 3+ (300 mg/dl ) by Multistics; incomplete remission type I, i.e. normal serum albumin levels (more than 30 g/l ) with a mean daily proteinuria of less than 1.0 g
Patients and design of treatment
for 7 consecutive days or + (30 mg/dl ) by Multistics; complete remission, i.e. daily proteinuria of less than 0.2 g We enrolled 86 Japanese patients (53 men and 33 women, with normal serum albumin levels. Renal dysfunction was aged 17-80 years, mean 44 years), who were admitted to the defined as a serum creatinine level of greater than First Department of Internal Medicine of Kanazawa 132.6 mmol/litre (1.5 mg/dl ) or glomerular filtration rate University Hospital or its affiliated hospitals between 1965 defined by endogenous creatinine clearance (C Cr ) of less than and 1988. We followed these patients for at least 5 years, or 60 ml/min. Renal death was defined as the necessity for until renal or actual death. Diagnosis was confirmed in all haemodialysis, peritoneal dialysis, or renal transplantation. patients by percutaneous needle renal biopsies. Patients with secondary membranous nephropathy such as lupus nephritis, or membranous nephropathy related to hepatitis B virus or Pathohistological studies malignancy were excluded from this study according to the clinical and laboratory findings. Between 1983 and 1988, 30 For light microscopic examination, kidney specimens were patients were given 1-3 courses of intravenous immune fixed in 10% phosphate-buffered formalin (pH 7.4), embedglobulin, 5-10 g/day (100-150 mg/kg/day) for 6 consecutive ded in paraffin, and cut into 4 mm sections. These specimens days, total dose 600-900 mg/kg (Fujisawa or Green Cross, were stained with haematoxylin and eosin (HE), periodic Osaka, Japan) in a non-blind and non-randomized manner. acid Schiff reagent (PAS), Mallory-azan, and periodic acid There were no significant differences between the intravenous silver methenamine (PAM ), and examined by light microimmune globulin treated group and non-immune globulin scopy, with an emphasis on capillary lesions. We determined (historical control ) group in clinical and laboratory back-the presence or absence of capillary-wall lesions and evalugrounds, as shown in Table 1 . Renal biopsies and treatments ated the appearance of lesions (double contour, bubble like were all conducted with the informed consent of the patients. appearance, and spike formation). Renal tissue specimens were examined by two observers with no knowledge of the patients' clinical courses to establish the diagnosis by stand-
Study design and response to treatment
ard pathological methods. In addition, immunofluorescent examination was also performed on all fresh frozen speciThis study is a retrospective analysis for the historical control group from 1965 to 1997. The immune globulin therapy mens, which were embedded in OCT compound, snap frozen in n-hexane cooled with a mixture of dry ice and acetone, group was followed from 1983 to 1998. Responses to treat- More than three glomeruli were examined in each specimen, and the intraglomerular immunofluorescence staining of immunoglobulins and complements were arbitrarily graded on a scale from 0 to 3: 0, none; 0.5, scattered; 1, weakly diffuse; 2, moderately diffuse; 3, strongly diffuse, and a mean score was calculated. One hundred and seven specimens were fixed with glutaraldehyde and osmium tetroxide, embedded in Epon ( Epok) 812 (Oken Shoji Co, Tokyo, Japan), cut into 0.1 mm sections, double-stained with uranyl acetate and lead citrate, and examined with a Hitachi H-600 electron microscope (Hitachi Co, Tokyo, Japan). For the electron microscopic study, we examined the specimens with an emphasis on the stage and synchronicity of subepithelial and intramembranous electrondense deposits. We modified the classification of Rosen et al. [16 ] , and arbitrarily classified specimens showing synchronous electron-dense deposits with a single stage as homogeneous type, and others having various stages of electron-dense deposits as heterogeneous type ( Figure 1 ).
Second biopsies were obtained from 20 patients 4 to 12 weeks after intravenous immune globulin therapy. Intensity of immunofluorescence and the character of subepithelial electron-dense deposits were compared between pre-and post-intravenous immune globulin therapy.
Laboratory investigations
We measured urinary protein quantitatively using the Pyrogallol red method, and semi-quantitatively using Multistics (Miles, Tokyo): −, negative; +, 30 mg/dl; 2+, 100 mg/dl; 3+, 300 mg/dl; 4+, 1000 mg/dl of albumin. Serum total protein, albumin, creatinine and immunoglobulin G (IgG ) levels were examined before and 1, 2, 4, 8, 16 and 24 weeks after intravenous immune globulin therapy. We also analysed circulating T lymphocyte subsets using flow cytometry (Ortho Spectrum III, Ortho Pharmaceutical Co., Raritan, New Jersey, USA) using monoclonal antibodies (CD4 (OKT4) and CD8 (OKT8), Ortho), and calculated the CD4/CD8 ratio. ( Table 1) . Of the controls, 17 patients were treated with corticosteroid alone and 22 patients with corticosteroid and immunosuppressants.
Statistical analysis

Results
Response to intravenous immune globulin therapy Patients' backgrounds
After intravenous globulin administration, serum IgG There was no difference in age, gender, or initial levels rose significantly from an initial 820±80 mg/dl clinicopathological state between the intravenous to 1390±100 mg/dl at 2 weeks (mean±SEM, immune globulin (n=30) and non-immune globulin P<0.005) and 1120±110 mg/dl at 4 weeks (P<0.01). groups (n=56) (70 vs 68% in nephrotic state; 37 vs Serum total protein and albumin levels gradually 39% in female, 50 vs 52% in homogeneous type, 50 vs increased to normal levels (more than 30g/l for albu-48% in heterogeneous type respectively. The follow-up period after treatment was significantly longer in the min) at 4 weeks post-treatment. These parameters had entered the normal ranges 24 months later No adverse effects were recorded during or after intravenous immune globulin therapy in any patients. (Figure 2a,b) . Proteinuria was unchanged at 4 weeks post-treatment (4.1±0.5 g/day before, 4.1±0.4 g/day at 2 weeks and 4.2±0.7 g/day at 4 weeks). The Changes in pathological findings following intravenous CD4/CD8 ratio of circulating T-lymphocyte subsets immune globulin therapy was initially elevated at 2.33±0.21 and quickly Following intravenous immune globulin therapy, 20 decreased to the normal range, 1.85±0.23 at 2 weeks patients underwent second renal biopsy 4 to 12 weeks and 1.73±0.18 at 4 weeks. The CD4/CD8 ratio conpost-treatment. No remarkable changes were seen in tinued to decrease until 6 months post-treatment in subepithelial IgG or electron-dense deposits. However, the complete remission group. However, these parathe intensity of glomerular C3c staining was significmeters returned to initial levels after 6 months in the antly reduced post-treatment (z value=−2.497, n= non-complete remission group ( Figure 2c) . 20, P=0.0125 by Wilcoxon's rank-sum test). In one Good responses were seen in 13 patients to intravenpatient who underwent a third renal biopsy at 9 months ous immune globulin therapy, defined as complete after three courses of intravenous immune globulin remission, and 17 patients had non-complete remission.
therapy, the intensity of the glomerular subepithelial Of the latter, 11 showed incomplete remission type II electron-dense deposits decreased as shown in with normal serum creatinine levels (<1.5 mg/dl ), Figure 3c . three patients had continued nephrotic state with renal dysfunction, and three entered end-stage renal failure. No significant differences were seen in age, previous Relationship between response to treatment and the therapy, dosages of intravenous immune globulin, or subtypes of membranous nephropathy clinical state between the complete and non-complete For the homogeneous type, intravenous immune globuremission groups. Patients showing homogeneous type lin more often induced remission at 6 months postelectron microscopic findings predominated in the treatment as compared with the control group (57 vs intravenous immune globulin therapy complete remis-10% respectively, P=0.0061). However, there was no sion group ( Table 2) . significant difference in early therapeutic effects for the Figure 3 shows the clinical course and electron heterogeneous type (13% for the intravenous immune microscopic findings of a representative patient with globulin vs 5% for the control group in remission after steroid-resistant prolonged nephrotic state and large 6 months), or the responses at 2 and 5 years in both synchronous electron-dense deposits, who had good subtypes. There was no difference in the final clinical response to intravenous immune globulin.
and functional outcomes between the two groups (renal globulin injection (600 mg/kg) reduced proteinuria by over 50% in rat Heymann nephritis, accompanied by reduction in glomerular C5b-9 and C3c staining and urinary C5b-9 excretion [15] . In this study, levels of proteinuria, glomerular IgG deposition and subepithelial electron-dense deposits were unchanged 4 weeks after intravenous immune globulin therapy, but glomerular C3c staining was reduced, as demonstrated with the rat Heymann nephritis model. In part, the therapeutic effects of intravenous immune globulin in human membranous nephropathy may be due to a reduction in ongoing complement activation in the glomerulus. In humans, the initial reduction of proteinuria during intravenous immune globulin therapy was unremarkable, but serum protein and albumin levels were increased 4 weeks after intravenous immune globulin therapy. Complete remission was achieved at 6 months in 13 patients. These findings suggest that intravenous immune globulin may ameliorate the glomerular injury in human membranous nephropathy not only by a reduction in complement activation in the initial phase, but also other mechanisms acting in the later phase. In this study, we found that circulating T lymphocyte subsets were altered before clinical improvements were seen in membranous nephropathy. The exact mechanism of this alteration in the CD4/CD8 ratio by intravenous immune globulin therapy is still unclear, but a normalization of T lymphocyte subsets may lead to accelerated antibody production by reducing discordant T lymphocyte function in human membranous nephropathy. In fact, intravenous immune globulin has been reported to decrease circulating specific antibodies in autoimmune diseases, such as anti-platelet antibodies in idiopathic thrombocytopenic purpura, or antineutrophilic antibodies in autoimmune neutropenia of infancy [20, 21] . In addition, Durandy et al. [22] reported that intravenous immune globulin given in a daily dose of 80 mg/kg to non-immunodeficient children for 15 days suppressed Pokeweed mitogen- stimulated differentiation and maturation of B lympho- Fig. 2 Alteration of serum protein, albumin, IgG levels, and circulat-cytes to plasma cells, with the effects lasting at least 5 ing T-lymphocyte subsets. (a) Serum total protein and albumin levels months. In this study, the CD4/CD8 ratio of circulating gradually increased and returned to the normal levels after treatment; T lymphocytes normalized at 4 weeks after intravenous (b) serum IgG levels rose significantly from 820±80 mg/dl to immune globulin therapy, the effect lasting at least 6 1390±100 mg/dl at 2 weeks and 1120±110 mg/dl at 4 weeks later; (c) the CD4/CD8 ratio of circulating T-lymphocyte subsets was months, with the exception of non-complete remission initially high at 2.33±0.21 and quickly decreased to the normal and relapsed patients. These long-term effects on the range after treatment. In non-complete remission patients (2), the immune system may lead to a reduction in immune- In this study, we arbitrarily divided human membranous nephropathy into two subtypes; homogeneous The mechanism(s) of therapeutic effects of intravenous immune globulin in immune-complex mediated dis-type and heterogeneous type based on their different patterns of subepithelial deposits and clinical courses. eases including lupus nephritis and membranous nephropathy has been speculated to involve the The heterogeneity of membranous nephropathy has been previously reported, and Rosen et al. [16 ] delinblocking of Fc receptors, anti-idiotype inhibition of pathogenic immunoglobulin, or the regulation of the eated the morphological and clinical patterns; short with one generation of deposits, short/repeated, complement cascade by preventing the binding of activated C3 to antibody-coated targets [11, 18, 19] . long/rapid, and long/slow. We simplified their classification with one generation of deposits, short/ Nangaku et al. found that even intraperitoneal immune (b) (c) (a) repeated, and long/rapid as the homogeneous type and ity in the latter continues beyond the long-term effects of intravenous immune globulin. long/slow as the heterogeneous type because of their synchronicity and clinical courses. The results of this Intravenous immune globulin has potential complications such as anaphylactic reactions, the risk of study, with most of the homogeneous type showing good clinical and renal functional outcomes, tend to contamination with unknown infective agents, and acute renal failure [23, 24] . In this study, such complicaconfirm the above arbitrary classification. In the longterm, intravenous immune globulin suppressed abnor-tions were not recorded and at these dosages intravenous immune globulin therapy is considered safe. The mal antibody production within 6 months, and induced clinical remission in the homogeneous type but not in cost of intravenous immune globulin therapy ($7600 for 1 course) may be higher than the cost of other the heterogeneous type, perhaps because disease activ-other therapies or repeated treatments with intravenous immune globulin therapy may be considered in the future.
In summary, our results suggest that short-term intravenous immune globulin therapy has the beneficial effect of giving earlier remission in a subtype of membranous nephropathy, patients with the homogeneous type showing synchronous electron-dense deposits, but does not change the long-term outcome in human membranous nephropathy.
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